Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 154

1.
2.

A computational method for designing diverse linear epitopes including citrullinated peptides with desired binding affinities to intravenous immunoglobulin.

Patro R, Norel R, Prill RJ, Saez-Rodriguez J, Lorenz P, Steinbeck F, Ziems B, Luštrek M, Barbarini N, Tiengo A, Bellazzi R, Thiesen HJ, Stolovitzky G, Kingsford C.

BMC Bioinformatics. 2016 Apr 8;17:155. doi: 10.1186/s12859-016-1008-7.

3.

High-Density Peptide Microarray Analysis of IgG Autoantibody Reactivities in Serum and Cerebrospinal Fluid of Multiple Sclerosis Patients.

Hecker M, Fitzner B, Wendt M, Lorenz P, Flechtner K, Steinbeck F, Schröder I, Thiesen HJ, Zettl UK.

Mol Cell Proteomics. 2016 Apr;15(4):1360-80. doi: 10.1074/mcp.M115.051664. Epub 2016 Feb 1.

PMID:
26831522
4.

Ultraviolet matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for phosphopeptide analysis with a solidified ionic liquid matrix.

Mukherjee G, Claudia Röwer C, Koy C, Protzel C, Lorenz P, Thiesen HJ, Hakenberg OW, Glocker MO.

Eur J Mass Spectrom (Chichester, Eng). 2015;21(2):65-77. doi: 10.1255/ejms.1362.

PMID:
26181280
5.

A novel strategy for the rapid preparation and isolation of intact immune complexes from peptide mixtures.

Al-Majdoub M, Opuni KF, Yefremova Y, Koy C, Lorenz P, El-Kased RF, Thiesen HJ, Glocker MO.

J Mol Recognit. 2014 Sep;27(9):566-74. doi: 10.1002/jmr.2375.

PMID:
25042711
6.

The B-subdomain of the Xenopus laevis XFIN KRAB-AB domain is responsible for its weaker transcriptional repressor activity compared to human ZNF10/Kox1.

Born N, Thiesen HJ, Lorenz P.

PLoS One. 2014 Feb 3;9(2):e87609. doi: 10.1371/journal.pone.0087609. eCollection 2014.

7.

Oxidatively modified LDL particles in the human placenta in early and late onset intrauterine growth restriction.

Pecks U, Rath W, Caspers R, Sosnowsky K, Ziems B, Thiesen HJ, Maass N, Huppertz B.

Placenta. 2013 Dec;34(12):1142-9.

PMID:
24404588
8.

miRNA expression profiles determined in maternal sera of patients with HELLP syndrome.

Stubert J, Koczan D, Richter DU, Dieterich M, Ziems B, Thiesen HJ, Gerber B, Reimer T.

Hypertens Pregnancy. 2014 May;33(2):215-35. doi: 10.3109/10641955.2013.858743. Epub 2013 Dec 4.

PMID:
24304191
9.

Epitope predictions indicate the presence of two distinct types of epitope-antibody-reactivities determined by epitope profiling of intravenous immunoglobulins.

Luštrek M, Lorenz P, Kreutzer M, Qian Z, Steinbeck F, Wu D, Born N, Ziems B, Hecker M, Blank M, Shoenfeld Y, Cao Z, Glocker MO, Li Y, Fuellen G, Thiesen HJ.

PLoS One. 2013 Nov 11;8(11):e78605. doi: 10.1371/journal.pone.0078605. eCollection 2013.

10.

Glatiramer acetate treatment effects on gene expression in monocytes of multiple sclerosis patients.

Thamilarasan M, Hecker M, Goertsches RH, Paap BK, Schröder I, Koczan D, Thiesen HJ, Zettl UK.

J Neuroinflammation. 2013 Oct 17;10:126. doi: 10.1186/1742-2094-10-126.

11.

MicroRNA expression changes during interferon-beta treatment in the peripheral blood of multiple sclerosis patients.

Hecker M, Thamilarasan M, Koczan D, Schröder I, Flechtner K, Freiesleben S, Füllen G, Thiesen HJ, Zettl UK.

Int J Mol Sci. 2013 Aug 5;14(8):16087-110. doi: 10.3390/ijms140816087.

12.
13.

Interferon-beta therapy in multiple sclerosis: the short-term and long-term effects on the patients' individual gene expression in peripheral blood.

Hecker M, Hartmann C, Kandulski O, Paap BK, Koczan D, Thiesen HJ, Zettl UK.

Mol Neurobiol. 2013 Dec;48(3):737-56. doi: 10.1007/s12035-013-8463-1. Epub 2013 May 1.

PMID:
23636981
14.

The advantage of specific intravenous immunoglobulin (sIVIG) on regular IVIG: experience of the last decade.

Svetlicky N, Ortega-Hernandez OD, Mouthon L, Guillevin L, Thiesen HJ, Altman A, Kravitz MS, Blank M, Shoenfeld Y.

J Clin Immunol. 2013 Jan;33 Suppl 1:S27-32. doi: 10.1007/s10875-012-9842-5. Epub 2012 Dec 11. Review.

PMID:
23229779
15.

Network analysis of transcriptional regulation in response to intramuscular interferon-β-1a multiple sclerosis treatment.

Hecker M, Goertsches RH, Fatum C, Koczan D, Thiesen HJ, Guthke R, Zettl UK.

Pharmacogenomics J. 2012 Aug;12(4):360. doi: 10.1038/tpj.2011.12. Epub 2011 Mar 29. No abstract available.

PMID:
22825046
16.

Cell type specificity of signaling: view from membrane receptors distribution and their downstream transduction networks.

He Y, Yu Z, Ge D, Wang-Sattler R, Thiesen HJ, Xie L, Li Y.

Protein Cell. 2012 Sep;3(9):701-13. doi: 10.1007/s13238-012-2049-y. Epub 2012 Jul 16.

PMID:
22802048
17.

Elevated type I interferon-like activity in a subset of multiple sclerosis patients: molecular basis and clinical relevance.

Hundeshagen A, Hecker M, Paap BK, Angerstein C, Kandulski O, Fatum C, Hartmann C, Koczan D, Thiesen HJ, Zettl UK.

J Neuroinflammation. 2012 Jun 22;9:140. doi: 10.1186/1742-2094-9-140.

18.

Integration of MicroRNA databases to study MicroRNAs associated with multiple sclerosis.

Angerstein C, Hecker M, Paap BK, Koczan D, Thamilarasan M, Thiesen HJ, Zettl UK.

Mol Neurobiol. 2012 Jun;45(3):520-35. doi: 10.1007/s12035-012-8270-0. Epub 2012 May 2.

PMID:
22549745
19.

Clonality characterization of natural epitope-specific antibodies against the tumor-related antigen topoisomerase IIa by peptide chip and proteome analysis: a pilot study with colorectal carcinoma patient samples.

Linnebacher M, Lorenz P, Koy C, Jahnke A, Born N, Steinbeck F, Wollbold J, Latzkow T, Thiesen HJ, Glocker MO.

Anal Bioanal Chem. 2012 Apr;403(1):227-38. doi: 10.1007/s00216-012-5781-5. Epub 2012 Feb 16.

PMID:
22349330
20.

Reassessment of blood gene expression markers for the prognosis of relapsing-remitting multiple sclerosis.

Hecker M, Paap BK, Goertsches RH, Kandulski O, Fatum C, Koczan D, Hartung HP, Thiesen HJ, Zettl UK.

PLoS One. 2011;6(12):e29648. doi: 10.1371/journal.pone.0029648. Epub 2011 Dec 27.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk